Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 8.134
Filter
1.
J Nanobiotechnology ; 22(1): 315, 2024 Jun 05.
Article in English | MEDLINE | ID: mdl-38840207

ABSTRACT

Chronic hepatitis B poses a significant global burden, modulating immune cells, leading to chronic inflammation and long-term damage. Due to its hepatotropism, the hepatitis B virus (HBV) cannot infect other cells. The mechanisms underlying the intercellular communication among different liver cells in HBV-infected individuals and the immune microenvironment imbalance remain elusive. Exosomes, as important intercellular communication and cargo transportation tools between HBV-infected hepatocytes and immune cells, have been shown to assist in HBV cargo transportation and regulate the immune microenvironment. However, the role of exosomes in hepatitis B has only gradually received attention in recent years. Minimal literature has systematically elaborated on the role of exosomes in reshaping the immune microenvironment of the liver. This review unfolds sequentially based on the biological processes of exosomes: exosomes' biogenesis, release, transport, uptake by recipient cells, and their impact on recipient cells. We delineate how HBV influences the biogenesis of exosomes, utilizing exosomal covert transmission, and reshapes the hepatic immune microenvironment. And based on the characteristics and functions of exosomes, potential applications of exosomes in hepatitis B are summarized and predicted.


Subject(s)
Exosomes , Hepatitis B virus , Hepatitis B, Chronic , Hepatocytes , Liver , Exosomes/immunology , Exosomes/metabolism , Humans , Hepatitis B virus/immunology , Liver/immunology , Liver/virology , Animals , Hepatitis B, Chronic/immunology , Hepatocytes/virology , Hepatocytes/immunology , Cell Communication , Cellular Microenvironment/immunology , Hepatitis B/immunology , Hepatitis B/virology
2.
BMC Infect Dis ; 24(1): 470, 2024 May 03.
Article in English | MEDLINE | ID: mdl-38702614

ABSTRACT

BACKGROUND: Hepatitis B virus (HBV) vaccination in Vietnamese adults remains low and unequally distributed. We conducted a study on HBV-naïve adults living in Ho Chi Minh City, Viet Nam, to determine barriers associated with HBV vaccination uptake after removing the financial barrier by providing free coupons for HBV vaccination. METHODS: After being screened for HBsAg, anti-HBs, and anti-HBc, 284 HBV-naïve study participants aged 18 and over (i.e., negative for HBsAg, anti-HBs, and anti-HBc total) were provided free 3-dose HBV vaccine coupons. Next, study participants' receipt of 1st, 2nd, and 3rd doses of HBV vaccine was documented at a pre-specified study healthcare facility, where HBV vaccines were distributed at no cost to the participants. Upon study entry, participants answered questionnaires on sociodemographics, knowledge of HBV and HBV vaccination, and related social and behavioral factors. The proportions of three doses of HBV vaccine uptake and their confidence intervals were analyzed. Associations of HBV vaccine initiation with exposures at study entry were evaluated using modified Poisson regression. RESULTS: 98.9% (281 of 284) of study participants had complete data and were included in the analysis. The proportion of participants obtaining the 1st, 2nd, and 3rd doses of HBV vaccine was 11.7% (95% Confidence Interval [95% CI] 8.0-15.5%), 10.7% (95%CI 7.1-14.3%), and 8.9% (95%CI 5.6-12.2%), respectively. On the other hand, participants were more likely to initiate the 1st dose if they had adequate knowledge of transmission (adjusted relative risk [aRR] = 2.58, 95% CI 1.12-5.92), adequate knowledge of severity (aRR = 6.75, 95%CI 3.38-13.48), and annual health-checking seeking behavior (aRR = 2.04, 95%CI 1.07-3.87). CONCLUSION: We documented a low HBV vaccination uptake despite incentivization. However, increased vaccine initiation was associated with better HBV knowledge and annual health check-up adherence. When considering expanding HBV vaccination to the general adult population, we should appreciate that HBV knowledge is an independent predictor of vaccine uptake.


Subject(s)
Health Knowledge, Attitudes, Practice , Hepatitis B Vaccines , Hepatitis B , Vaccination , Humans , Male , Female , Adult , Hepatitis B Vaccines/administration & dosage , Hepatitis B/prevention & control , Vietnam , Vaccination/statistics & numerical data , Vaccination/psychology , Middle Aged , Young Adult , Adolescent , Surveys and Questionnaires , Patient Acceptance of Health Care/statistics & numerical data , Hepatitis B virus/immunology
3.
Clin Lab ; 70(5)2024 May 01.
Article in English | MEDLINE | ID: mdl-38747904

ABSTRACT

BACKGROUND: Hepatitis B caused by hepatitis B virus (HBV) infection is a serious global public health issue. Currently, serological indicators serve as important markers for the diagnosis of hepatitis B. It has been found that HBV core-related antigen (HBcrAg) correlates well with intrahepatic cccDNA, intrahepatic HBV DNA, serum HBV DNA, and hepatitis B e antigen (HBeAg). To provide a more reliable basis for the diagnosis and treatment of hepatitis B, we explored the correlation between HBcrAg and conventional serologic testing indicators and disease staging. METHODS: Five hundred forty-two patient serum samples were collected at the First Affiliated Hospital of Soochow University from November 2021 to March 2022. The serum HBcrAg was measured by the magnetic particle chemiluminescence method in addition with other serum indicators. RESULTS: HBcrAg statistically correlated with HBV DNA level (r = 0.655, p < 0.001) and HBeAg level (r = 0.945, p < 0.001. The mean HBcrAg levels in the immune-tolerant and immune-clearance phases were significantly higher than those in the immunologic-control phase and the reactivation phase. This study demonstrated that serum HBcrAg positively correlated with serum HBV DNA and HBeAg. Even in cases where HBV DNA and HBeAg are negative, there is still a higher positivity rate of HBcrAg in hepatitis B patients. CONCLUSIONS: HBcrAg is a reliable serum marker to avoid underdiagnosis of occult HBV infection.


Subject(s)
Biomarkers , DNA, Viral , Hepatitis B Core Antigens , Hepatitis B e Antigens , Hepatitis B virus , Hepatitis B , Humans , Hepatitis B Core Antigens/blood , Hepatitis B Core Antigens/immunology , Male , Female , Hepatitis B/diagnosis , Hepatitis B/immunology , Hepatitis B/blood , Hepatitis B/virology , Hepatitis B e Antigens/blood , Hepatitis B e Antigens/immunology , Hepatitis B virus/immunology , Hepatitis B virus/genetics , Adult , Biomarkers/blood , Middle Aged , DNA, Viral/blood , Young Adult , Aged , Adolescent
4.
J Med Virol ; 96(5): e29670, 2024 May.
Article in English | MEDLINE | ID: mdl-38773810

ABSTRACT

This study aimed to assess the predictive capacity of emerging serological markers, serum HBV RNA and HBcrAg, for HBeAg seroconversion in children with HBeAg-positive chronic hepatitis B (CHB). Treatment-naïve HBeAg-positive CHB children who admitted to the Liver Disease Center of Hunan Children's Hospital between April 2021 and September 2022 and received treatment with the combined entecavir and interferon-alpha treatment were recruited. Serum HBV RNA and HBcrAg were measured at baseline and Weeks 12, 24, and 48 of treatment. Our study showed that serum HBV RNA (HR = 0.71, 95% CI: 0.56-0.91, p = 0.006), HBcrAg (HR = 0.60, 95% CI: 0.43-0.84, p = 0.003), and HBsAg (HR = 0.49, 95%CI: 0.36-0.69, p < 0.001) at Week 12 were independent predictors of HBeAg seroconversion. ROC curve analysis presented that serum HBV RNA decline value (ΔHBV RNA) at Week 36 and HBcrAg decline value (ΔHBcrAg) at Week 12 (AUC = 0.871, p = 0.003 and AUC = 0.810, p = 0.003, respectively) could effectively predict HBeAg seroconversion. Furthermore, the optimal critical values were determined and the children with ΔHBV RNA > 3.759 log10 copies/mL at Week 36 or ΔHBcrAg >0.350 log10 U/mL at Week 12 more likely to achieve HBeAg seroconversion. The serum HBV RNA and HBcrAg provide new insights into the treatment of CHB in children. Early assessment of serum HBV RNA and HBcrAg during treatment can assist clinical decision-making and optimize individualized therapeutic approaches.


Subject(s)
Antiviral Agents , Hepatitis B e Antigens , Hepatitis B virus , Hepatitis B, Chronic , RNA, Viral , Seroconversion , Humans , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Hepatitis B, Chronic/blood , Male , Female , Child , Hepatitis B e Antigens/blood , Antiviral Agents/therapeutic use , RNA, Viral/blood , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Adolescent , Interferon-alpha/therapeutic use , Child, Preschool , Biomarkers/blood , Guanine/therapeutic use , Guanine/analogs & derivatives , Hepatitis B Core Antigens/blood , Hepatitis B Core Antigens/immunology , ROC Curve
5.
World J Gastroenterol ; 30(17): 2294-2297, 2024 May 07.
Article in English | MEDLINE | ID: mdl-38813053

ABSTRACT

Chronic viral hepatitis causes an increased risk of progressive liver disease and hepatocellular carcinoma. On the wave of the World Health Organization's goal to reduce new cases and deaths from hepatitis B and C by 2030, there is an increasing call to expand the indications for treatment of chronic hepatitis B. Currently, the main goal of treatment is to achieve a functional cure due to the inability of current drugs to completely eradicate the virus. There are still many discrepancies between available guidelines in terms of eligibility for treatment as well as an uncertainty about the appropriate treatment duration. This editorial addresses key questions about the topic and whether indications for treatment should be expanded.


Subject(s)
Antiviral Agents , Hepatitis B virus , Hepatitis B, Chronic , Liver Neoplasms , Practice Guidelines as Topic , Humans , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Hepatitis B, Chronic/diagnosis , Antiviral Agents/therapeutic use , Antiviral Agents/adverse effects , Hepatitis B virus/drug effects , Hepatitis B virus/immunology , Liver Neoplasms/virology , Liver Neoplasms/therapy , Carcinoma, Hepatocellular/virology , Treatment Outcome , Patient Selection
6.
Biol Pharm Bull ; 47(5): 941-945, 2024.
Article in English | MEDLINE | ID: mdl-38735754

ABSTRACT

Hepatitis B virus reactivation (HBV-R) is a serious complication that can occur in patients with resolved HBV infection during cancer chemotherapy. We examined the levels of HBV surface antibody (HBsAb) and HBV core antibody (HBcAb) to assess the incidence of HBV-R in cancer patients including hematopoietic stem cell transplantation (HSCT) and rituximab administration. This retrospective cohort study included 590 patients with resolved HBV infection. The incidence of HBV-R was evaluated 761.5 (range, 90-3898) days after the inititiation of chemotherapy. Of the patients, 13 (2.2%) developed HBV-R after the start of chemotherapy. All 13 patients exhibited lower HBsAb (<100 mIU/mL) levels at baseline. A higher level of HBcAb (≥100 cut off index (C.O.I.)) was a possible risk factor for HBV-R as well as HSCT and rituximab administration. The simultaneous presence of HBsAb <100 mIU/mL and HBcAb ≥100 C.O.I. increased the risk of HBV-R by 18.5%. Patients treated with rituximab were at a higher risk of HBV-R (18.4%) despite having HBcAb <100 C.O.I. Our results suggest that assessment of HBsAb and HBcAb levels prior to the chemotherapy is important for identifying patients at high risk of HBV-R, especially in solid cancers without HSCT and rituximab administration.


Subject(s)
Hepatitis B Antibodies , Hepatitis B Surface Antigens , Hepatitis B virus , Hepatitis B , Rituximab , Virus Activation , Humans , Male , Female , Middle Aged , Retrospective Studies , Hepatitis B Antibodies/blood , Hepatitis B Antibodies/immunology , Hepatitis B virus/immunology , Hepatitis B virus/physiology , Virus Activation/drug effects , Rituximab/therapeutic use , Rituximab/adverse effects , Adult , Aged , Hepatitis B/immunology , Hepatitis B Surface Antigens/blood , Hepatitis B Surface Antigens/immunology , Hematopoietic Stem Cell Transplantation/adverse effects , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/adverse effects , Young Adult , Neoplasms/drug therapy , Neoplasms/immunology , Hepatitis B Core Antigens/immunology , Hepatitis B Core Antigens/blood , Aged, 80 and over , Adolescent
7.
Front Cell Infect Microbiol ; 14: 1382029, 2024.
Article in English | MEDLINE | ID: mdl-38817443

ABSTRACT

Infections of hepatotropic viruses cause a wide array of liver diseases including acute hepatitis, chronic hepatitis and the consequently developed cirrhosis and hepatocellular carcinoma (HCC). Among the five classical hepatotropic viruses, hepatitis B virus (HBV) and hepatitis C virus (HCV) usually infect human persistently and cause chronic hepatitis, leading to major troubles to humanity. Previous studies have revealed that several types of inflammasomes are involved in the infections of HBV and HCV. Here, we summarize the current knowledge about their roles in hepatitis B and C. NLRP3 inflammasome can be activated and regulated by HBV and HCV. It is found to exert antiviral function or mediates inflammatory response in viral infections depending on different experimental models. Besides NLRP3 inflammasome, IFI16 and AIM2 inflammasomes participate in the pathological process of hepatitis B, and NALP3 inflammasome may sense HCV infection in hepatocytes. The inflammasomes affect the pathological process of viral hepatitis through its downstream secretion of inflammatory cytokines interleukin-1ß (IL-1ß) and IL-18 or induction of pyroptosis resulting from cleaved gasdermin D (GSDMD). However, the roles of inflammasomes in different stages of viral infection remains mainly unclear. More proper experimental models of viral hepatitis should be developed for specific studies in future, so that we can understand more about the complexity of inflammasome regulation and multifunction of inflammasomes and their downstream effectors during HBV and HCV infections.


Subject(s)
Hepacivirus , Hepatitis B virus , Hepatitis B, Chronic , Hepatitis C, Chronic , Inflammasomes , NLR Family, Pyrin Domain-Containing 3 Protein , Humans , Inflammasomes/metabolism , Inflammasomes/immunology , Hepatitis C, Chronic/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Hepacivirus/immunology , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/metabolism , Hepatitis B virus/immunology , DNA-Binding Proteins/metabolism , Interleukin-1beta/metabolism , Pyroptosis , Animals , Phosphoproteins/metabolism , Nuclear Proteins/metabolism , Hepatocytes/virology , Hepatocytes/immunology , Interleukin-18/metabolism , Phosphate-Binding Proteins/metabolism , Gasdermins
8.
Clin Res Hepatol Gastroenterol ; 48(6): 102369, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38719147

ABSTRACT

BACKGROUND AND AIM: Hepatitis B virus (HBV) infection presents with indicators of varying clinical significance. We aimed to evaluate the correlation among HBV Pre-S1 antigen (HBV PreS1-Ag), HBV e antigen (HBeAg), HBV DNA, and alanine aminotransferase (ALT) levels. METHODS: We retrospectively analyzed 6180 serum samples collected between 2020 and 2022 at the Shanghai General Hospital, China. Data regarding PreS1-Ag, HBeAg, ALT, and HBV DNA were compiled. Correlation analyses and cross-tabulations were employed to explore the diagnostic indicators. RESULTS: The detection rates of both antigen indicators showed a proportional increase with HBV DNA loads. The correlation between PreS1-Ag and HBV DNA (r = 0.616) was stronger than that between HBeAg and HBV DNA (r = 0.391). The specificity of PreS1-Ag (84.30 %) was lower than that of HBeAg (97.44 %), whereas the sensitivity of HBeAg (91.13 %) significantly surpassed that of PreS1-Ag (29.56 %). Among the HBV DNA positive patients, 92.04 % tested positive for at least one indicator, which exceeded the rate of PreS1+HBeAg- and PreS1-HBeAg+ (52. 28 % and 68. 56 %, respectively). Only 1.75 % of the patients exhibited double negativity, which was lower than the percentage of patients with single negativity (1.95 % and 12.00 % for PreS1-Ag and HBeAg, respectively). The PreS1 levels correlated with ALT levels (r = 0.317); patients with PreS1-positive status had higher ALT levels than patients with PreS1-negative status. CONCLUSION: PreS1-Ag is a more robust HBV replication indicator than HBeAg. PreS1-Ag displayed high sensitivity, whereas HBeAg demonstrated high specificity. Moreover, PreS1-Ag levels correlated with ALT levels. A combination of these indicators demonstrated dependable clinical value for detecting HBV infection and evaluating liver function.


Subject(s)
Alanine Transaminase , DNA, Viral , Hepatitis B Surface Antigens , Hepatitis B e Antigens , Hepatitis B virus , Humans , Retrospective Studies , Hepatitis B e Antigens/blood , DNA, Viral/blood , Alanine Transaminase/blood , Female , Male , Hepatitis B Surface Antigens/blood , Adult , Middle Aged , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis B/blood , Hepatitis B/diagnosis , Young Adult , Aged , Protein Precursors
9.
Int Immunopharmacol ; 134: 112219, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38733823

ABSTRACT

BACKGROUNDS & AIMS: Given its ability to inhibit HBV replication, Interferon alpha (IFN-α) treatment has been confirmed to be effective in managing Chronic Hepatitis B (CHB). However, its underlying mechanisms are incompletely understood. METHODS: Herein, we investigated the antiviral properties of IFN-α by introducing IFN-α expression plasmids into a well-established HBV Hydrodynamic Injection (HDI) mouse model and examined the impact of IFN-α or hepcidin treatment on macrophages derived from THP-1 cells. The cytokine profiles were analyzed using the cytometry microsphere microarray technology, and flow cytometry was used to analyze the polarization of macrophages. Additionally, the IL-6/JAK2/STAT3 signaling pathway and the hepcidin-ferroportin axis were analyzed to better understand the macrophage polarization mechanism. RESULTS: As evidenced by the suppression of HBV replication, injection of an IFN-α expression plasmid and supernatants of IFN-α-treated macrophages exerted anti-HBV effects. The IFN-α treatment up-regulated IL-6 in mice with HBV replication, as well as in IFN-α-treated HepG2 cells and macrophages. Furthermore, JAK2/STAT3 signaling and hepcidin expression was promoted, inducing iron accumulation via the hepcidin-ferroportin axis, which caused the polarization of M1 macrophages. Furthermore, under the effect of IFN-α, IL-6 silencing or blockade downregulated the JAK2/STAT3 signaling pathway and hepcidin, implying that increased hepcidin expression under IFN-α treatment was dependent on the IL-6/JAK2/STAT3 pathway. CONCLUSION: The IL-6/JAK2/STAT3 signaling pathway is activated by IFN-α which induces hepcidin expression. The resulting iron accumulation then induces the polarization of M1 macrophages via the hepcidin-ferroportin axis, yielding an immune response which exerts antiviral effects against HBV replication.


Subject(s)
Antiviral Agents , Hepatitis B virus , Hepcidins , Interferon-alpha , Janus Kinase 2 , Macrophages , STAT3 Transcription Factor , Hepcidins/metabolism , Hepcidins/genetics , Animals , Humans , Interferon-alpha/pharmacology , Macrophages/immunology , Macrophages/drug effects , Hepatitis B virus/physiology , Hepatitis B virus/drug effects , Hepatitis B virus/immunology , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Mice , Janus Kinase 2/metabolism , STAT3 Transcription Factor/metabolism , Hep G2 Cells , Signal Transduction/drug effects , Interleukin-6/metabolism , THP-1 Cells , Mice, Inbred C57BL , Virus Replication/drug effects , Male , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Disease Models, Animal , Hepatitis B/immunology , Hepatitis B/drug therapy , Hepatitis B/virology , Cation Transport Proteins/metabolism , Cation Transport Proteins/genetics
10.
J Infect Public Health ; 17(6): 1095-1099, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38705062

ABSTRACT

BACKGROUND: Health care workers (HCWs) are at increased risk of exposure to hepatitis B virus (HBV). The most effective prevention measure is vaccination, with a serum hepatitis B surface antibody (HBsAb) titre > 10 mIU/ml considered protective. To date, the sociodemographic and occupational characteristics related to HBV serosusceptibility and factors associated with booster hesitancy remain unclear. Therefore, this study aimed to identify factors associated with maintaining a protective HBsAb titre in a large sample of HCWs and to evaluate factors potentially associated with hesitancy towards vaccine boosters. METHODS: A cross-sectional study was conducted among HCWs who underwent a health surveillance visit between 2017 and 2022. If the serum HBsAb titre was < 10 MIU/ml, a vaccine booster dose was offered. Based on their willingness to be vaccinated, employees were classified into three groups: acceptance, hesitation, and refusal. Uni- and multivariable analyses were performed to assess the association of demographic and occupational characteristics with serosusceptibility and attitudes towards vaccination. RESULTS: A total of 1632 (27%) employees were shown to be nonimmune. A lower median age and being a physician were significantly associated with a protective HBsAb titre. A total of 706 nonimmune employees (43.3%) accepted the vaccination, 865 (53%) hesitated, and 61 (3.7%) refused. The median age of those who refused vaccination was significantly higher than that of those who hesitated and those who were vaccinated. Acceptance of vaccination was significantly higher among nurses, while nurse aides hesitated more; among nonmedical graduate staff both hesitation and refusal were higher than expected. In the multivariable analysis, higher age, female sex, and employment as an allied health care professional were shown to be significantly associated with hesitation/refusal, while being born abroad turned out to be protective. CONCLUSIONS: Our study showed that approximately a quarter of HCWs were not immune to HBV infection, and of these, more than half were hesitant towards or refused the booster dose. The risk of hesitation/refusal was higher with age in women and among allied health care staff. Based on these findings, further studies are needed to prospectively evaluate HBV seroprevalence, vaccination adherence, factors associated with hesitancy, and the effectiveness of health surveillance strategies in a high-risk population susceptible to infection.


Subject(s)
Health Personnel , Hepatitis B Antibodies , Hepatitis B Vaccines , Hepatitis B , Immunization, Secondary , Vaccination Hesitancy , Humans , Cross-Sectional Studies , Male , Female , Italy , Health Personnel/statistics & numerical data , Health Personnel/psychology , Adult , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Middle Aged , Immunization, Secondary/statistics & numerical data , Hepatitis B Antibodies/blood , Vaccination Hesitancy/statistics & numerical data , Vaccination Hesitancy/psychology , Vaccination/statistics & numerical data , Vaccination/psychology , Young Adult , Hepatitis B virus/immunology
11.
PLoS One ; 19(5): e0303945, 2024.
Article in English | MEDLINE | ID: mdl-38776335

ABSTRACT

Killer cell lectin-like receptor G1 (KLRG1) has traditionally been regarded as an inhibitory receptor of T cell exhaustion in chronic infection and inflammation. However, its exact role in hepatitis B virus (HBV) infection remains elusive. CD8+ T cells from 190 patients with chronic hepatitis B were analyzed ex vivo for checkpoint and apoptosis markers, transcription factors, cytokines and subtypes in 190 patients with chronic hepatitis B. KLRG1+ and KLRG1- CD8+ T cells were sorted for transcriptome analysis. The impact of the KLRG1-E-cadherin pathway on the suppression of HBV replication mediated by virus-specific T cells was validated in vitro. As expected, HBV-specific CD8+ T cells expressed higher levels of KLRG1 and showed an exhausted molecular phenotype and function. However, despite being enriched for the inhibitory molecules, thymocyte selection-associated high mobility group box protein (TOX), eomesodermin (EOMES), and Helios, CD8+ T cells expressing KLRG1 produced significant levels of tumour necrosis factor (TNF)-α, interferon (IFN)-γ, perforin, and granzyme B, demonstrating not exhausted but active function. Consistent with the in vitro phenotypic assay results, RNA sequencing (RNA-seq) data showed that signature effector T cell and exhausted T cell genes were enriched in KLRG1+ CD8+ T cells. Furthermore, in vitro testing confirmed that KLRG1-E-cadherin binding inhibits the antiviral efficacy of HBV-specific CD8+ T cells. Based on these findings, we concluded that KLRG1+ CD8+ T cells are not only a terminally exhausted subgroup but also exhibit functional diversity, despite inhibitory signs in HBV infection.


Subject(s)
CD8-Positive T-Lymphocytes , Hepatitis B virus , Hepatitis B, Chronic , Lectins, C-Type , Receptors, Immunologic , Humans , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Lectins, C-Type/metabolism , Lectins, C-Type/genetics , Receptors, Immunologic/metabolism , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Female , Male , Hepatitis B virus/immunology , Adult , Middle Aged , Virus Replication , Cadherins/metabolism , Cadherins/genetics , Perforin/metabolism , Perforin/genetics
12.
Viruses ; 16(5)2024 04 29.
Article in English | MEDLINE | ID: mdl-38793588

ABSTRACT

This systematic review investigates the immunosuppressive environment in HBV-associated hepatocellular carcinoma (HCC), characterized by dysfunctional and exhausted HBV-specific T cells alongside an increased infiltration of HBV-specific CD4+ T cells, particularly regulatory T cells (Tregs). Heightened expression of checkpoint inhibitors, notably PD-1, is linked with disease progression and recurrence, indicating its potential as both a prognostic indicator and a target for immunotherapy. Nevertheless, using PD-1 inhibitors has shown limited effectiveness. In a future perspective, understanding the intricate interplay between innate and adaptive immune responses holds promise for pinpointing predictive biomarkers and crafting novel treatment approaches for HBV-associated HCC.


Subject(s)
Adaptive Immunity , Carcinoma, Hepatocellular , Hepatitis B virus , Liver Neoplasms , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/virology , Humans , Liver Neoplasms/immunology , Liver Neoplasms/virology , Hepatitis B virus/immunology , T-Lymphocytes, Regulatory/immunology , Programmed Cell Death 1 Receptor/immunology , Immune Checkpoint Inhibitors/therapeutic use , Immune Checkpoint Inhibitors/pharmacology , Hepatitis B/immunology , Hepatitis B/virology , Hepatitis B/complications , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Hepatitis B, Chronic/complications , CD4-Positive T-Lymphocytes/immunology , T-Lymphocytes/immunology , Immunotherapy
13.
Viruses ; 16(5)2024 04 30.
Article in English | MEDLINE | ID: mdl-38793596

ABSTRACT

The concurrent seropositivity of HBsAg and anti-HBs has been described among patients with chronic hepatitis B (CHB), but its prevalence is variable. HBV S-gene mutations can affect the antigenicity of HBsAg. Patients with mutations in the 'α' determinant region of the S gene can develop severe HBV reactivation under immunosuppression. In this study at a tertiary liver center in the United States, we evaluated the frequency and virological characteristics of the HBsAg mutations among CHB patients with the presence of both HBsAg and anti-HBs. In this cohort, 45 (2.1%) of 2178 patients were identified to have a coexistence of HBsAg and anti-HBs, and 24 had available sera for the genome analysis of the Pre-S1, Pre-S2, and S regions. The frequency of mutations in the S gene was significantly higher among those older than 50 years (mean 8.5 vs. 5.4 mutations per subject, p = 0.03). Twelve patients (50%) had mutations in the 'α' determinant region of the S gene. Mutations at amino acid position 126 were most common in eight subjects. Three had a mutation at position 133. Only one patient had a mutation at position 145-the classic vaccine-escape mutation. Despite the universal HBV vaccination program, the vaccine-escape mutant is rare in our cohort of predominantly Asian patients.


Subject(s)
Hepatitis B Antibodies , Hepatitis B Surface Antigens , Hepatitis B virus , Hepatitis B, Chronic , Mutation , Tertiary Care Centers , Humans , Hepatitis B Surface Antigens/genetics , Hepatitis B Surface Antigens/immunology , Female , Male , Middle Aged , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Adult , Hepatitis B Antibodies/blood , Hepatitis B Antibodies/immunology , Hepatitis B, Chronic/virology , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/epidemiology , United States/epidemiology , Immune Evasion/genetics , Aged , Prevalence , Young Adult
14.
Viruses ; 16(5)2024 05 07.
Article in English | MEDLINE | ID: mdl-38793619

ABSTRACT

BACKGROUND AND AIMS: The outcomes of HBV infections are related to complex immune imbalances; however, the precise mechanisms by which HBV induces immune dysfunction are not well understood. METHODS: HBV transgenic (HBs-Tg) mice were used to investigate intrahepatic NK cells in two distinct subsets: conventional NK (cNK) and liver-resident NK (LrNK) cells during a chronic HBV infection. RESULTS: The cNK cells, but not the LrNK cells, were primarily responsible for the increase in the number of bulk NK cells in the livers of ageing HBs-Tg mice. The hepatic cNK cells showed a stronger ability to produce IL-10, coupled with a higher expression of CD69, TIGIT and PD-L1, and lower NKG2D expression in ageing HBs-Tg mice. A lower mitochondrial mass and membrane potential, and less polarized localization were observed in the hepatic cNK cells compared with the splenic cNK cells in the HBs-Tg mice. The enhanced galectin-3 (Gal-3) secreted from HBsAg+ hepatocytes accounted for the IL-10 production of hepatic cNK cells via ITGB1 signaling. For humans, LGALS3 and ITGB1 expression is positively correlated with IL-10 expression, and negatively correlated with the poor clinical progression of HCC. CONCLUSIONS: Gal-3-ITGB1 signaling shapes hepatic cNK cells but not LrNK cells during a chronic HBV infection, which may correlate with HCC progression.


Subject(s)
Carcinoma, Hepatocellular , Galectin 3 , Hepatitis B virus , Interleukin-10 , Killer Cells, Natural , Liver Neoplasms , Liver , Mice, Transgenic , Signal Transduction , Animals , Mice , Killer Cells, Natural/immunology , Humans , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Interleukin-10/genetics , Interleukin-10/metabolism , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/virology , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/immunology , Liver Neoplasms/virology , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , Liver/pathology , Liver/immunology , Liver/virology , Liver/metabolism , Galectin 3/genetics , Galectin 3/metabolism , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Disease Progression , Male , Female , Hepatocytes/virology , Hepatocytes/metabolism , Hepatocytes/immunology , Mice, Inbred C57BL , Galectins/genetics , Galectins/metabolism
15.
Viruses ; 16(5)2024 05 08.
Article in English | MEDLINE | ID: mdl-38793623

ABSTRACT

Hepatitis B virus (HBV) is a major driver of chronic hepatic inflammation, which regularly leads to liver cirrhosis or hepatocellular carcinoma. Immediate innate immune cell response is crucial for the rapid clearance of the infection. Here, natural killer (NK) cells play a pivotal role in direct cytotoxicity and the secretion of antiviral cytokines as well as regulatory function. The aim of this study was to further elucidate NK cell responses triggered by an HBV infection. Therefore, we optimized HBV in vitro models that reliably stimulate NK cells using hepatocyte-like HepG2 cells expressing the Na+-taurocholate co-transporting polypeptide (NTCP) and HepaRG cells. Immune cells were acquired from healthy platelet donors. Initially, HepG2-NTCP cells demonstrated higher viral replication compared to HepaRG cells. Co-cultures with immune cells revealed increased production of interferon-γ and tumor necrosis factor-α by NK cells, which was no longer evident in isolated NK cells. Likewise, the depletion of monocytes and spatial separation from target cells led to the absence of the antiviral cytokine production of NK cells. Eventually, the combined co-culture of isolated NK cells and monocytes led to a sufficient cytokine response of NK cells, which was also apparent when communication between the two immune cell subpopulations was restricted to soluble factors. In summary, our study demonstrates antiviral cytokine production by NK cells in response to HBV+ HepG2-NTCP cells, which is dependent on monocyte bystander activation.


Subject(s)
Coculture Techniques , Cytokines , Hepatitis B virus , Hepatitis B , Killer Cells, Natural , Monocytes , Humans , Killer Cells, Natural/immunology , Monocytes/immunology , Monocytes/virology , Hepatitis B virus/immunology , Hepatitis B virus/physiology , Cytokines/metabolism , Hep G2 Cells , Hepatitis B/immunology , Hepatitis B/virology , Virus Replication , Interferon-gamma/metabolism , Interferon-gamma/immunology , Tumor Necrosis Factor-alpha/metabolism , Hepatocytes/virology , Hepatocytes/immunology
16.
J Med Virol ; 96(6): e29692, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38804172

ABSTRACT

To achieve a virological cure for hepatitis B virus (HBV), innovative strategies are required to target the covalently closed circular DNA (cccDNA) genome. Guanine-quadruplexes (G4s) are a secondary structure that can be adopted by DNA and play a significant role in regulating viral replication, transcription, and translation. Antibody-based probes and small molecules have been developed to study the role of G4s in the context of the human genome, but none have been specifically made to target G4s in viral infection. Herein, we describe the development of a humanized single-domain antibody (S10) that can target a G4 located in the PreCore (PreC) promoter of the HBV cccDNA genome. MicroScale Thermophoresis demonstrated that S10 has a strong nanomolar affinity to the PreC G4 in its quadruplex form and a structural electron density envelope of the complex was determined using Small-Angle X-ray Scattering. Lentiviral transduction of S10 into HepG2-NTCP cells shows nuclear localization, and chromatin immunoprecipitation coupled with next-generation sequencing demonstrated that S10 can bind to the HBV PreC G4 present on the cccDNA. This research validates the existence of a G4 in HBV cccDNA and demonstrates that this DNA secondary structure can be targeted with high structural and sequence specificity using S10.


Subject(s)
DNA, Circular , DNA, Viral , G-Quadruplexes , Hepatitis B virus , Single-Domain Antibodies , Humans , Hepatitis B virus/genetics , Hepatitis B virus/immunology , DNA, Circular/genetics , DNA, Viral/genetics , Hep G2 Cells , Single-Domain Antibodies/genetics , Single-Domain Antibodies/immunology , Single-Domain Antibodies/chemistry , Genome, Viral , Promoter Regions, Genetic , Virus Replication , Hepatitis B/virology
17.
J Gen Virol ; 105(5)2024 05.
Article in English | MEDLINE | ID: mdl-38757942

ABSTRACT

Since its discovery in 1965, our understanding of the hepatitis B virus (HBV) replication cycle and host immune responses has increased markedly. In contrast, our knowledge of the molecular biology of hepatitis delta virus (HDV), which is associated with more severe liver disease, is less well understood. Despite the progress made, critical gaps remain in our knowledge of HBV and HDV replication and the mechanisms underlying viral persistence and evasion of host immunity. The International HBV Meeting is the leading annual scientific meeting for presenting the latest advances in HBV and HDV molecular virology, immunology, and epidemiology. In 2023, the annual scientific meeting was held in Kobe, Japan and this review summarises some of the advances presented at the Meeting and lists gaps in our knowledge that may facilitate the development of new therapies.


Subject(s)
Hepatitis B virus , Hepatitis B , Hepatitis Delta Virus , Virus Replication , Hepatitis B virus/genetics , Hepatitis B virus/physiology , Hepatitis B virus/immunology , Humans , Hepatitis Delta Virus/genetics , Hepatitis Delta Virus/physiology , Hepatitis B/virology , Hepatitis B/immunology , Molecular Biology , Japan , Hepatitis D/virology , Host-Pathogen Interactions/immunology , Host-Pathogen Interactions/genetics
18.
Immunobiology ; 229(3): 152810, 2024 May.
Article in English | MEDLINE | ID: mdl-38772101

ABSTRACT

BACKGROUND AND AIMS: Activation of the cGAS-STING pathway induces the production of type I interferons, initiating the antiviral immune response, which contributes to the clearance of pathogens. Previous studies have shown that STING agonists promote hepatitis B virus (HBV) clearance; however, few studies have investigated the effect of activating the cGAS-STING pathway in macrophages on HBV. METHODS: The polarization status of HBV particle-stimulated RAW264.7 macrophages was analyzed. After stimulation with HBV particles, the analysis focused on determining whether the DNA sensors in RAW264.7 macrophages recognized the viral double-stranded DNA (dsDNA) and evaluating the activation of the cGAS-STING pathway. Coculture of mouse macrophages and hepatocytes harboring HBV was used to study the antiviral activity of HBV-stimulated RAW264.7 macrophages. RESULTS: After stimulation with HBV particles, HBV relaxed circular DNA (rcDNA) was detected in RAW264.7 macrophages, and the protein expression of phospho-STING, phospho-TBK1, and phospho-IRF3 in the STING pathway was increased, as shown by Western blot analysis, which revealed that M1 polarization of macrophages was caused by increased expression of CD86. RT-PCR analyses revealed elevated expression of M1 macrophage polarization-associated cytokines such as TNFα, IL-1ß, iNOS, and IFNα/ß. In the coculture experiment, both HBsAg and HBeAg expression levels were significantly decreased in AML12-HBV1.3 cells cocultured with the supernatants of HBV-stimulated RAW264.7 macrophages. CONCLUSION: The results suggest that macrophages can endocytose HBV particles. Additionally, viral dsDNA can be recognized by DNA pattern recognition receptors, which in turn activate the cGAS-STING pathway, promoting the M1 polarization of macrophages, while no significant M2 polarization is observed. Macrophages stimulated with HBV particles exhibit enhanced antiviral activity against HBV.


Subject(s)
DNA, Viral , Hepatitis B virus , Macrophages , Membrane Proteins , Nucleotidyltransferases , Signal Transduction , Hepatitis B virus/physiology , Hepatitis B virus/immunology , Animals , Nucleotidyltransferases/metabolism , Mice , Macrophages/immunology , Macrophages/virology , Macrophages/metabolism , Membrane Proteins/metabolism , RAW 264.7 Cells , Hepatitis B/immunology , Hepatitis B/virology , Humans , Macrophage Activation/immunology , Hepatocytes/virology , Hepatocytes/immunology , Hepatocytes/metabolism , Interferon Regulatory Factor-3/metabolism
20.
Front Immunol ; 15: 1340619, 2024.
Article in English | MEDLINE | ID: mdl-38711498

ABSTRACT

To design new CARs targeting hepatitis B virus (HBV), we isolated human monoclonal antibodies recognizing the HBV envelope proteins from single B cells of a patient with a resolved infection. HBV-specific memory B cells were isolated by incubating peripheral blood mononuclear cells with biotinylated hepatitis B surface antigen (HBsAg), followed by single-cell flow cytometry-based sorting of live, CD19+ IgG+ HBsAg+ cells. Amplification and sequencing of immunoglobulin genes from single memory B cells identified variable heavy and light chain sequences. Corresponding immunoglobulin chains were cloned into IgG1 expression vectors and expressed in mammalian cells. Two antibodies named 4D06 and 4D08 were found to be highly specific for HBsAg, recognized a conformational and a linear epitope, respectively, and showed broad reactivity and neutralization capacity against all major HBV genotypes. 4D06 and 4D08 variable chain fragments were cloned into a 2nd generation CAR format with CD28 and CD3zeta intracellular signaling domains. The new CAR constructs displayed a high functional avidity when expressed on primary human T cells. CAR-grafted T cells proved to be polyfunctional regarding cytokine secretion and killed HBV-positive target cells. Interestingly, background activation of the 4D08-CAR recognizing a linear instead of a conformational epitope was consistently low. In a preclinical model of chronic HBV infection, murine T cells grafted with the 4D06 and the 4D08 CAR showed on target activity indicated by a transient increase in serum transaminases, and a lower number of HBV-positive hepatocytes in the mice treated. This study demonstrates an efficient and fast approach to identifying pathogen-specific monoclonal human antibodies from small donor cell numbers for the subsequent generation of new CARs.


Subject(s)
Hepatitis B Surface Antigens , Hepatitis B virus , Humans , Hepatitis B virus/immunology , Hepatitis B virus/genetics , Animals , Mice , Hepatitis B Surface Antigens/immunology , Receptors, Chimeric Antigen/immunology , Receptors, Chimeric Antigen/genetics , Receptors, Chimeric Antigen/metabolism , Antibodies, Monoclonal/immunology , Immunotherapy, Adoptive , Hepatitis B/immunology , Hepatitis B/virology , Broadly Neutralizing Antibodies/immunology , B-Lymphocytes/immunology , T-Lymphocytes/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...